Dr. Reddy’s Buys Progynova HRT Brands in India to Bolster Gynecology Portfolio
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dr Reddy’s Laboratories ( (RDY) ) has issued an announcement.
On February 18, 2026, Dr. Reddy’s Laboratories announced it had entered into a definitive agreement with UK-based Mercury Pharma Group to acquire the Indian trademarks and related assets of hormone replacement therapy brands Progynova® and Cyclo-Progynova® for USD 32.15 million. Progynova®, an estradiol valerate oral HRT and the leading estradiol brand in India with IQVIA MAT December 2025 sales of about INR 100 crore, together with Cyclo-Progynova®, will strengthen Dr. Reddy’s gynecology portfolio and mark a strategic foray into the hormone replacement therapy segment in the domestic market, enhancing its presence in women’s health and branded specialty treatments.
The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India, established in 1984. It provides APIs, generics, branded generics, biosimilars and OTC products, with key therapeutic focuses including gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology, and major markets spanning the U.S., India, Russia & CIS, China, Brazil and Europe.
Average Trading Volume: 1,464,003
Technical Sentiment Signal: Buy
Current Market Cap: $11.65B
For an in-depth examination of RDY stock, go to TipRanks’ Overview page.
